Taysha Gene Therapies Revenue 2020-2024 | TSHA
Taysha Gene Therapies revenue from 2020 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Taysha Gene Therapies Annual Revenue
(Millions of US $) |
| 2023 |
$15 |
| 2022 |
$3 |
| 2021 |
$ |
| 2020 |
$ |
| 2019 |
$ |
Taysha Gene Therapies Quarterly Revenue
(Millions of US $) |
| 2024-09-30 |
$2 |
| 2024-06-30 |
$1 |
| 2024-03-31 |
$3 |
| 2023-12-31 |
$4 |
| 2023-09-30 |
$5 |
| 2023-06-30 |
$2 |
| 2023-03-31 |
$5 |
| 2022-12-31 |
|
| 2022-09-30 |
|
| 2022-06-30 |
|
| 2022-03-31 |
|
| 2021-12-31 |
|
| 2021-09-30 |
|
| 2021-06-30 |
|
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
|
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.434B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
